Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6402 posts found.

stocks1

Weekly Movers: Regulus, Nymox, Akers…

July 4, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shares, drug trial, markets, stocks

Shares in Regulus Therapeutics (Nasdaq: RGLS) dropped after the company said it has received verbal notification from the US Food …
Feature
astrazeneca_building_white

AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront

July 1, 2016 Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Deals, Licencing, Loe Pharna, Valeant, drug development

UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an …
News

US doctors received $6.5 billion from drug, device firms in 2015

July 1, 2016 Medical Communications, Research and Development, Sales and Marketing US, affordable care act, pharma, regulation

Doctors and hospitals received nearly $6.5 billion in research and speaking fees as well as other goods or services from …
News
abpilogo1

UK healthcare professionals received £340.3 million in benefits from pharma industry in 2015 discloses ABPI

July 1, 2016 Business Services, Medical Communications, Sales and Marketing ABPI, Pharmacutical, corruption, disclosure, regulation

“We don’t want our neighbours to know what we earn,” said Mike Thompson, the chief executive of industry body Association …
News
abbvie_0

AbbVie’s Imbruvica secures fourth breakthrough therapy designation from US FDA

July 1, 2016 Medical Communications, Research and Development, Sales and Marketing AbbVie, US FDA, drug trial, imbruvica

US pharma firm AbbVie (NYSE: ABBV) said the US Food and Drug Administration has granted Imbruvica a fourth breakthrough therapy …
News
shire_image

Shire says Phase II trial for rare eye condition in premature infants fails

July 1, 2016 Medical Communications, Research and Development Shire, US FDA, drug trial, rare eye condition in infants

Shire plc (LSE: SHP) said its drug compound to treat a rare eye condition in infants failed mid-stage trials. The …
News
astellas_imageuk

Astellas UK suspended from ABPI for “deception” and other cultural failings

June 24, 2016 Medical Communications, Research and Development, Sales and Marketing ABPI, Astellas, cultural failings

Astellas UK has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for a period …
News

Nice rejects AstraZeneca’s Tagrisso for lung cancer in preliminary recommendation

June 24, 2016 Medical Communications, Research and Development AstraZeneca, CDF, NICE, lung cancer, regulation

UK drugmaker AstraZeneca (LSE: AZN) said the National Institute for Health and Care Excellence (Nice) has rejected Tagrisso (osimertinib) to …
News
brexit

“Immediate challenges” for UK pharma post-Brexit, says ABPI

June 24, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, brexit

The UK life sciences industry has expressed dismay at the result of the EU referendum, but has pledged to work …
News
allergan

FDA approves expanded label for Allergan’s Avycaz

June 24, 2016 Medical Communications, Research and Development, Sales and Marketing Allergan, Avycaz, FDA, expanded label

Allergan (NYSE: FDA) has announced that the US Food and Drug Administration (FDA) has approved its supplemental new drug application …
News
cancer

Genmab’s CLL drug gets negative opinion from EMA committee

June 24, 2016 Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer

Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …
News
celgene_1_02

Nice rejects Celgene’s drug to treat blood cancer

June 24, 2016 Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer

The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …
News
eu

EU referendum outcome will have major consequences for UK’s pharma sector – GlobalData

June 23, 2016 Medical Communications, Sales and Marketing EMA, GlobalData, Pharma sector, brexit, referendum

The outcome of today’s referendum on the UK’s continuing membership of the European Union (EU) will have major consequences for …
News

Murdo Gordon gets Chief Commercial Officer role at Bristol-Myers Squibb

June 21, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, chief commercial officer

Bristol-Myers Squibb (NYSE: BMY) has announced the appointment of Munro Gordon as executive vice president and chief commercial officer, effective …
Appointment
esteban

Amgen appoints Esteban Santos as executive VP of operations

June 20, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Amgen (NASDAQ: AMGN) has announced the appointment of Esteban Santos as executive vice president, operations. Santos will be responsible for …
Appointment
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025